Materials and Methods: Between 2008 and 2017, 21 patients who underwent resection due to earlystage SCLC were evaluated retrospectively in the study. 16 (76.2%) stage I and 5 (23.8%) stage II patients were included in the study. All patients received adjuvant therapy after surgery.
Results: Sixteen (76.2%) male and 5 (23.8) female patients were included in the study. The mean age was 60.19 ± 7.13 years. Patients were followed for a mean of 33 months. There was 16 (76.2%) small cell, and 5 (23.6%) combined small cell carcinoma. The 5-year survival rate was 48.6% (59.6 ± 10.6 months). In 7 patients (33.3%) postoperative morbidity was observed. No statistically significant difference was found between N status and survival. Statistically significant differences were found between tumors smaller than 1 cm and tumors greater than 1 cm in terms of T stage (p = 0.043).
Conclusions: In conclusion, multimodal treatment is very important for survival in early-stage small cell lung cancer. Although our results in our study are aggressive tumors of the SCLC, survival outcomes in the early stages are quite satisfactory. Early stage survival outcomes, especially after stage I tumors, are as successful as non-small cell lung cancers.
Keywords : small cell lung cancer, lobectomy, prognostic factors